ArticleThe New England journal of medicine2019
Treatment of Progressive Multifocal Leukoencephalopathy with Nivolumab.
Article in The New England journal of medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- JC Polyomavirus Infection: A Narrative Review.Infectious diseases and therapy · 2025Review
- Article
- Progressive multifocal leukoencephalopathy after CAR-T cell therapy.Bone marrow transplantation · 2024Article
- Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy in China.Journal of neurovirology · 2023Article
- Progressive Multifocal Leukoencephalopathy Treated by Immune Checkpoint Inhibitors.Annals of neurology · 2023Article
- Long-term outcome of progressive multifocal leukoencephalopathy with recombinant interleukin-2 treatment and an associated increase in the number of HPyV-2-specific T-cells: a case report.Therapeutic advances in hematology · 2023Article
- Promise and Challenges of Checkpoint Inhibitor Therapy for Progressive Multifocal Leukoencephalopathy in HIV.Current HIV/AIDS reports · 2022Review
- Article
- The foundations of immune checkpoint blockade and the ipilimumab approval decennial.Nature reviews. Drug discovery · 2022Review
- [Immune checkpoint inhibitors in the treatment of progressive multifocal leukoencephalopathy].Der Nervenarzt · 2022Article
- Innovative therapeutic concepts of progressive multifocal leukoencephalopathy.Journal of neurology · 2022Review
- It was 40 Years Ago Today: AIDS and the Brain.Neurocritical care · 2022Article
- Pembrolizumab treatment of inflammatory progressive multifocal leukoencephalopathy: a report of two cases.Journal of neurovirology · 2022Article
- Leveraging Systems Immunology to Optimize Diagnosis and Treatment of Inborn Errors of Immunity.Frontiers in systems biology · 2022Article
- Advances in Treatment of Progressive Multifocal Leukoencephalopathy.Annals of neurology · 2021Review
- Article
- Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: a new gold standard?Journal of neurology · 2021Article
- Allogeneic BK Virus-Specific T-Cell Treatment in 2 Patients With Progressive Multifocal Leukoencephalopathy.Neurology(R) neuroimmunology & neuroinflammation · 2021Article
- Immune Reconstitution Syndrome After Nivolumab for Progressive Multifocal Leukoencephalopathy.Neurology. Clinical practice · 2021Article
- Adoptive Transfer of JC Virus-Specific T Lymphocytes for the Treatment of Progressive Multifocal Leukoencephalopathy.Annals of neurology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
30969500What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.